

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI110569

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	SECURITY INTEREST	
CONVEYING PARTY DATA		
Name		Execution Date
RK PHARMA INC.		03/14/2024
RECEIVING PARTY DATA		
Company Name:	CITIBANK, N.A.	
Street Address:	388 Greenwich Street	
Internal Address:	26 Floor	
City:	New York	
State/Country:	NEW YORK	
Postal Code:	10013	
PROPERTY NUMBERS Total: 26		
Property Type	Number	
Patent Number:	10442813	
Patent Number:	11110073	
Patent Number:	11111208	
Patent Number:	11260065	
Patent Number:	11324771	
Patent Number:	11332495	
Patent Number:	11447499	
Patent Number:	11447513	
Patent Number:	11654151	
Patent Number:	11707443	
Patent Number:	11850224	
Application Number:	18462619	
Application Number:	18682785	
Application Number:	16804177	
Application Number:	16893869	
Application Number:	17079554	
Application Number:	17075736	
Application Number:	17124668	
Application Number:	17034030	

Property Type	Number
Application Number:	17394832
Application Number:	17355876
Application Number:	17354373
Application Number:	17023544
Application Number:	17874838
Application Number:	18328397
Application Number:	18218610

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2122371035

Email: mclain@windelsmarx.com, cmcbride@windelsmarx.com

Correspondent Name: Mr. Michael J. Clain

Address Line 1: 156 West 56th Street

Address Line 4: New York, NEW YORK 10019

NAME OF SUBMITTER:	CANDI MCBRIDE
--------------------	---------------

SIGNATURE:	CANDI MCBRIDE
------------	---------------

DATE SIGNED:	05/08/2024
--------------	------------

	This document serves as an Oath/Declaration (37 CFR 1.63).
--	--

Total Attachments: 14

source=[FINAL] RK Pharma - IP Security Agreement (12289231)#page1.tif
source=[FINAL] RK Pharma - IP Security Agreement (12289231)#page2.tif
source=[FINAL] RK Pharma - IP Security Agreement (12289231)#page3.tif
source=[FINAL] RK Pharma - IP Security Agreement (12289231)#page4.tif
source=[FINAL] RK Pharma - IP Security Agreement (12289231)#page5.tif
source=[FINAL] RK Pharma - IP Security Agreement (12289231)#page6.tif
source=[FINAL] RK Pharma - IP Security Agreement (12289231)#page7.tif
source=[FINAL] RK Pharma - IP Security Agreement (12289231)#page8.tif
source=[FINAL] RK Pharma - IP Security Agreement (12289231)#page9.tif
source=[FINAL] RK Pharma - IP Security Agreement (12289231)#page10.tif
source=[FINAL] RK Pharma - IP Security Agreement (12289231)#page11.tif
source=[FINAL] RK Pharma - IP Security Agreement (12289231)#page12.tif
source=[FINAL] RK Pharma - IP Security Agreement (12289231)#page13.tif
source=[FINAL] RK Pharma - IP Security Agreement (12289231)#page14.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (this “Agreement”) is made as of March 14, 2024, by and among RK PHARMA INC., a Delaware corporation (“RK Pharma”); RK PHARMA SOLUTIONS LLC, a New Jersey limited liability company (“RK Solutions”, and together with RK Pharma, each individually a “Debtor” and together the “Debtors”); and CITIBANK, N.A. (together with its successors, the “Secured Party”).

W I T N E S S E T H:

WHEREAS, concurrently herewith, the Debtors, ARCHIS PHARMA LLC, a Delaware limited liability company, VGYAAN PHARMACEUTICALS LLC, a New Jersey limited liability company, APICORE LLC, a New Jersey limited liability company (the foregoing, collectively, the “Credit Parties”), and the Secured Party are entering into a LOAN, SECURITY AGREEMENT AND GUARANTY dated as of the date hereof (as it may be amended, restated, amended and restated, supplemented, restructured or otherwise modified, renewed or replaced from time to time, the “Credit Agreement”) and pursuant to which the Secured Party is agreeing to extend credit to certain of the Credit Parties (the “Borrowers”) on the terms and subject to the conditions specified therein and pursuant to which, among other things, each Debtor is granting to the Secured Party a security interest in and lien on substantially all of such Debtor’s assets, including, but not limited to, all of such Debtor’s patents, patent applications, copyrights, copyright applications, trademarks, trademark applications, service marks, trade names, mask works, trade secrets, licenses of any of the foregoing and any right to use any of the foregoing (collectively, the “Intellectual Property”); and

WHEREAS, the execution and delivery of this Agreement by the Debtors is a condition precedent to the effectiveness of the Credit Agreement and the extension of credit by the Secured Party to the Borrowers; and

NOW, THEREFORE, in consideration of the above premises, and in order to induce the Secured Party to make loans or other advances to the Borrowers from time to time hereafter, and for other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, each Debtor hereby represents, warrants, covenants and agrees as follows:

1. Definitions. The Credit Agreement and the provisions thereof are hereby incorporated herein in their entirety by this reference thereto. Capitalized terms that are defined in the Credit Agreement and are used but not defined herein shall have the respective meanings given thereto in the Credit Agreement.

2. Assignment for Security. To secure the prompt payment and performance of the Obligations, each Debtor hereby collaterally assigns, pledges and grants to the Secured Party a continuing security interest in and to and lien on all of such Debtor’s Intellectual Property (including, without limitation, the Intellectual Property listed on Schedule A attached hereto), whether now owned or existing or hereafter acquired or arising and wheresoever located, and all proceeds thereof (such as, by way of example but not limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights

corresponding to any of the Intellectual Property throughout the world, the goodwill of such Debtor's business connected with the use of and symbolized by any trademarks, and all re-issues, divisions, continuations, renewals, extensions, and continuations-in-part thereof (collectively, the "Intellectual Property Collateral").

3. Existing Intellectual Property. As of the date hereof, the Intellectual Property listed on Schedule A constitutes all of the Intellectual Property now owned by each Debtor for which such Debtor has registered or filed an application with the United States Patent and Trademark Office or the United States Copyright Office.

4. Rights and Remedies. The security interest granted hereby is granted in conjunction with the security interest granted to the Secured Party under the Credit Agreement. The rights and remedies of the Secured Party with respect to the security interest granted hereby are in addition to those set forth in the Credit Agreement, and those which are now or hereafter available to the Secured Party as a matter of law or equity. Each right, power and remedy of the Secured Party provided for herein or in the Credit Agreement, or now or hereafter existing at law or in equity, shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by the Secured Party of any one or more of the rights, powers or remedies provided for in this Agreement or the Credit Agreement, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including the Secured Party, of any or all other rights, powers or remedies.

5. Limitation on Duty. Beyond the exercise of reasonable care in the custody and preservation thereof, the Secured Party will have no duty as to any Intellectual Property in its possession or control or in the possession or control of any agent or bailee or any income therefrom or as to the preservation of rights against prior parties or any other rights pertaining thereto. The Secured Party will be deemed to have exercised reasonable care in the custody and preservation of the Intellectual Property in its possession or control if such property is accorded treatment substantially equal to that which it accords its own property, and will not be liable or responsible for any loss or damage to any Intellectual Property, or for any diminution in the value thereof, by reason of any act or omission of any agent or bailee selected by the Secured Party in good faith or by reason of any act or omission by the Secured Party pursuant to instructions from the Secured Party, except to the extent that such liability arises from the Secured Party's gross negligence or willful misconduct.

6. Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page of this Agreement by fax transmission or e-mail transmission (e.g. "pdf" or "tif") shall be effective as delivery of a manually executed counterpart of this Agreement. Without limiting the foregoing, to the extent a manually executed counterpart is not specifically required to be delivered under the terms of any Loan Document, upon the request of any party, such fax transmission or e-mail transmission shall be promptly followed by such manually executed counterpart

The words "delivery," "execute," "execution," "signed," "signature," and words of like import in any document executed in connection herewith shall be deemed to include electronic

signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Secured Party, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act; provided, that, notwithstanding anything contained herein to the contrary the Secured Party is under no obligation to agree to accept electronic signatures in any form or in any format unless expressly agreed to by the Secured Party pursuant to procedures approved by it; provided, further, that, without limiting the foregoing, upon the request of the Secured Party, any electronic signature shall be promptly followed by such manually executed counterpart.

7. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of each Debtor, the Secured Party, all future holders of the Obligations and their respective successors and assigns, except that no Debtor may assign or transfer any of its rights or obligations under this Agreement without the prior written consent of the Secured Party.

8. Severability. If any part of this Agreement is contrary to, prohibited by, or deemed invalid under applicable laws or regulations, such provision shall be inapplicable and deemed omitted to the extent so contrary, prohibited or invalid, but the remainder hereof shall not be invalidated thereby and shall be given effect so far as possible.

9. Headings. The Section headings contained in this Agreement are and shall be without substantive meaning or content of any kind whatsoever and are not a part of the agreement between the parties hereto.

10. GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the laws of the State of New York applied to contracts to be performed wholly within the State of New York. Any judicial proceeding brought by or against any Debtor or the Secured Party with respect to any of the Obligations, this Agreement or any other Loan Document may be brought in any court of competent jurisdiction in the State of New York, United States of America, and, by execution and delivery of this Agreement, each Debtor and the Secured Party accepts for itself and in connection with its properties, generally and unconditionally, the non-exclusive jurisdiction of the aforesaid courts, and irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. Each Debtor hereby waives personal service of any and all process upon it and consents that all such service of process may be made by registered mail (return receipt requested) directed to such Debtor at its address set forth in the Credit Agreement and service so made shall be deemed completed five (5) days after the same shall have been so deposited in the mails of the United States of America. Nothing herein shall affect the right to serve process in any manner permitted by law or shall limit the right of the Secured Party to bring proceedings against any Debtor in the courts of any other jurisdiction. Each Debtor and the Secured Party waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. Any judicial proceeding by any Debtor against the Secured Party involving, directly or indirectly, any matter or claim in any way

arising out of, related to or connected with this Agreement or any other Loan Document, shall be brought only in a federal or state court located in the City of New York, State of New York.

11. WAIVER OF JURY TRIAL. EACH DEBTOR HEREBY SUBMITS TO THE NONEXCLUSIVE JURISDICTION OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK AND OF ANY NEW YORK STATE COURT SITTING IN NEW YORK COUNTY FOR PURPOSES OF ALL LEGAL PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.


12. WAIVER OF VENUE. EACH DEBTOR IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF THE VENUE OF ANY SUCH PROCEEDING BROUGHT IN SUCH A COURT AND ANY CLAIM THAT ANY SUCH PROCEEDING BROUGHT IN SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. EACH DEBTOR AND THE SECURED PARTY EACH HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

[Balance of page intentionally left blank; signature page follows]


IN WITNESS WHEREOF, this Agreement has been duly executed as of the day and year first above written.

DEBTOR:

RK PHARMA, INC.

By: 
Name: Ravishanker Kovi
Title: Executive Chairman and Secretary

RK PHARMA SOLUTIONS LLC

By: 
Name: Ravishanker Kovi
Title: President, Chief Executive Officer and Secretary

SECURED PARTY:

CITIBANK, N.A.

By: _____
Name: Raj Mathur
Title:

IN WITNESS WHEREOF, this Agreement has been duly executed as of the day and year first above written.

DEBTOR:

RK PHARMA, INC.


By: _____
Name: Ravishanker Kovi
Title: Executive Chairman and Secretary

RK PHARMA SOLUTIONS LLC

By: _____
Name: Ravishanker Kovi
Title: President, Chief Executive Officer and Secretary

SECURED PARTY:

CITIBANK, N.A.

By:  _____
Name: Raj Mathur
Title: **SVP**

Signature page to Intellectual Property Security Agreement

PATENT
REEL: 067343 FRAME: 0096

SCHEDULE A
Intellectual Property

Trademarks:

Name of Credit Party	Trademark	Country	Application no	Status
RK PHARMA SOLUTIONS LLC	RK PHARMA	Japan	1540916	Published/Approved
RK PHARMA SOLUTIONS LLC	RK PHARMA	WIPO	1540916	Published/Approved
RK Pharma Inc.	ZUEINO	USA	97185552	Published/Approved

Patents:

Product	Title	Patent country	Application No/ Publication no/ Patent no	Priority date (dd/mm/yy)			Filing date (dd/mm/yy)			Status	Indian application / US application/ EU application	Applicant/Assignee
Rucaparib Camsylate	Novel polymorph of Rucaparib Camsylate and method of making same.	India	IN 374175	30	Jan	2018	28	Jan	2019	Granted	IN 201821003485	RK PHARMA SOLUTIONS LLC
		India	IN 201821013649	10	Apr	2018	28	Jan	2019	Abandoned	IN 201821013649	RK PHARMA SOLUTIONS LLC
		USA	US 10,442,813	30	Jan	2018	29	Jan	2019	Granted	16260978	RK Pharma Inc
Thiotepa	Storage-stable ready-to-use injectable formulations of thiotepa	USA	US 11,260,065	28	Nov	2018	21	Nov	2019	Granted	16690696	RK Pharma Inc
Fosaprepitant dimeglumine	Storage-stable ready-to-use injectable formulations of Fosaprepitant dimeglumine	USA	US 20200316097	28	Feb	2019	28	Feb	2020	Published	16804177	RK Pharma Inc

Selezipag	A Stable pharmaceutical composition of Selezipag	India	IN 482639	8	May	2019	11	May	2020	Granted	IN 201921018865	RK PHARMA SOLUTIONS LLC
		USA	US 20210069187	8	May	2019	5	Jun	2020	Published	16893869	RK Pharma Inc
Eribulin mesylate	Improved process for the preparation of Eribulin Mesylate Intermediate. Process for the preparation of Eribulin mesylate	India	IN 377543	14	Jun	2019	13	Jun	2020	Granted	IN 201921023560	RK PHARMA SOLUTIONS LLC
		USA	US 20180009825				5	July	2017	Abandoned	15641831	RK Pharma Inc
		USA	US 11,447,499	14	Jun	2019	11	Jun	2020	Granted	16898794	RK Pharma Inc
		India	IN 449046	17	Jun	2019	17	Jun	2020	Granted	IN 201921023977	RK PHARMA SOLUTIONS LLC
Safinamide mesylate	Improved process for the preparation of Safinamide mesylate Intermediate	India	IN 449046	17	Jun	2019	17	Jun	2020	Granted	IN 201921023977	RK PHARMA SOLUTIONS LLC
		USA	US 11,111,208	12	Jun	2019	12	Jun	2020	Granted	16899903	RK Pharma Inc
Degarelix	Improved process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix	India	IN 431502	21	Sept	2019	20	Sept	2020	Granted	IN 201921038164	RK PHARMA SOLUTIONS LLC
		USA	US 11,332,495	21	Sept	2019	15	Sept	2020	Granted	17020983	RK Pharma Inc
Methylene blue	Improved process for the purification of Methylene blue	India	IN 455651	21	Sept	2019	20	Sept	2020	Granted	IN 201921038163	RK PHARMA SOLUTIONS LLC
		USA	US 20220049102	21	Sept	2019	17	Sept	2020	Published	17023544	RK Pharma Inc
		EP	EP3795565A1	-	-	-	21	Sept	2020	Published	EP20197268	RK PHARMA SOLUTIONS LLC
Trabectedin	Storage-stable ready-to-use injectable formulations of Trabectedin	India	IN 462333	21	Oct	2019	21	Oct	2020	Granted	IN 201921042699	RK PHARMA SOLUTIONS LLC
		USA	US 20210169873	-	-	-	21	Oct	2020	Published	17075736	RK Pharma Inc
Tigecycline	Storage-stable ready-to-use formulations of Tigecycline	India	IN 201921042698	21	Oct	2019	21	Oct	2020	Withdrawn	IN 201921042698	RK PHARMA SOLUTIONS LLC
		USA	US 11,654,151	-	-	-	21	Oct	2020	Granted	17075734	RK Pharma Inc
Ferric malto	Novel polymorphic form of Ferric malto	India	IN 201921043623	26	Oct	2019	19	Oct	2020	Published	IN 201921043623	RK PHARMA SOLUTIONS LLC
		USA	US 20210139518	-	-	-	26	Oct	2020	Published	17079554	RK Pharma Inc

Melpalalan	Ready to Use Injectable formulations of Melpalalan and processes for preparation thereof.	India	IN 201921052782	19	Dec	2019	21	Dec	2020	Published	IN 201921052782	RK PHARMA SOLUTIONS LLC
		USA	US 20210205216	19	Dec	2019	17	Dec	2020		17124668	RK Pharma Inc
Ferric carboxymaltose	Purification process of Ferric carboxymaltose	USA	US 11,447,513				10	Feb	2021	Granted	17174286	RK Pharma Inc
Ferric carboxymaltose	Purification process of Ferric carboxymaltose	India	IN 399237	12	Feb	2020	10	Feb	2021	Granted	IN 202021006073	RK PHARMA SOLUTIONS LLC
Hydroxocobalamin hydrochloride	Improved process for the preparation of Hydroxocobalamin hydrochloride	India	IN 405666	12	Feb	2020	22	Jun	2020	Granted	IN 202021006047	RK PHARMA SOLUTIONS LLC
		USA	US 11,324,771	-	-	-	24	Jun	2020	Granted	16910560	RK Pharma Inc
Degarelix	Sterile Degarelix acetate-Mannitol premix and process for the preparation same	India	IN 202021008664	28	Feb	2020	15	Sept	2020	Complete	IN 202021008664	RK PHARMA SOLUTIONS LLC
Ferric citrate	Improved process for the preparation of ferric citrate	India	IN 463353	26	Apr	2020	2	Oct	2020	Granted	IN 202021017797	RK PHARMA SOLUTIONS LLC
		USA	US20210332073	-	-	-	28	Sept	2020	Published	17034030	RK Pharma Inc
Micafungin	Stable ready-to-use injectable formulations of Micafungin Sodium	USA	US20220040092	27	Jun	2020	10	Feb	2022	Published	17355876	RK Pharma Inc
Acyclovir sodium	Stable Acyclovir Sodium Parenteral Formulation	USA	US20220040100	25	Jun	2020	22	June	2021	Published	17354373	RK Pharma Inc
Ferumoxytol	Novel process for the isolation of Ferumoxytol	India	IN 202121004060	29	Jan	2021	29	Jan	2021	Published	IN 202121004060	RK PHARMA SOLUTIONS LLC
Chlorothiazide Sodium	Improved process for the preparation of Chlorothiazide pre-mix	India	IN 202121029752	2	Jul	2021	16	6	2022	Published	IN 202121029752	Apicore Pharmaceuticals Pvt Ltd

PATENT

REEL: 067343 FRAME: 0099

Ferric maltol	Composition of ferric maltol for oral administration	India	IN 202141035636	6	Aug	2021	22	July	2022	Published	IN 202141035636	RK Pharma Inc
Ferric Maltol	Improved process for the preparation of Ferric maltol	USA	US 20230054302	6	Aug	2021	27	July	2022	Published	1/874838	RK Pharma Inc
Lurbenectedin	Improved process for the preparation of Lurbenectedin	India	WO 2023/047195				26	May	2022	Published	IN 202141042716	RK Pharma Inc/ Apicore Pharma
Lurbenectedin	Improved process for the preparation of Lurbenectedin	India	PCT/IB2022/059343	15	Nov	2021	15	Nov	2021	PCT filed	IN 202141052219	RK Pharma Inc/ Apicore Pharma
Lurbenectedin	2-Improved process for the preparation of Lurbenectedin	India	PCT/IB2022/059343	14	Jan	2022	14	Jan	2022	PCT filed	IN 202241002229	RK Pharma Inc/ Apicore Pharma
Ferric maltol	Improved process for the preparation of Ferric maltol	India	WO 2023/047195				26	May	2022	Published	IN 202241008728	RK Pharma Inc/ Apicore Pharma
Selenious acid	Improved process for the preparation of Selenious acid	India	IN 202221012917	9	3	2022	22	2	2023	Complete	IN 202221012917	RK Pharma Inc/ Apicore Pharma
Cetorelix	Cetorelix RTU Formulations	PCT	WO 2023/017326				26	5	2022	Published	63231822	RK Pharma Inc
Cetorelix	Improved process for the preparation of Cetorelix	India	IN 202241025975	4	5	2022	4	5	2023	Complete	IN 202241025975	RK Pharma Inc/ Apicore Pharma
Isavacozonium sulphate	Improved process for Isacuvzonium sulphate	India	IN 202221038870	6	7	2022				Published	IN 202221038870	RK Pharma Inc
Lanreotide	Improved process for the prepraation of Lanreotide	India	IN 202241045524	9	8	2022				Complete	IN 202241045524	RK Pharma Inc
Selegiline	Improved process for the preparation of Selegiline	India	IN 202221031754				2	6	2022	Complete	IN 202221031754	RK Pharma Inc
Ganirelix acetate	Improved process for the preparation of Ganirelix acetate	India	IN 202221035937				23	6	2022	Complete	IN 202221035937	RK Pharma Inc/ Apicore Pharma
Ferumoxytol	Improved process for the preparation of Ferumoxytol	India	IN 202221027702				13	5	2022	Complete	IN 202221027702	RK Pharma Inc

PATENT

Lurbinectedin	3-Improved process for the preparation of Lurbinectedin- amorphous form	India	PCT/IB2022/059343	5	5	2022				PCT filed	IN 202221026266	RK Pharma Inc/Apicore Pharma
Dimetindine	Improved process for the preparation of Dimetindine	India	IN 202241027009				10	5	2022	Complete	IN 202241027009	RK Pharma Inc/Apicore Pharma
Ferric maltol	Improved Process and Polymorphs (NI)	PCT	WO 2023/047195				26	5	2022	Published	PCT/IB2022/054961	RK Pharma Inc/Apicore Pharma
Prucalopride succinate	Improved process for the preparation of Prucalopride	India	IN 202221031756	2	6	2022	17	5	2023	Complete	IN 202221031756	RK Pharma Inc/Apicore Pharma
Lurbinectedin	Improved process for the preparation of Lurbinectedin- and its Polymorphic form	PCT	PCT/IB2022/059343				30	9	2022	PCT filed	PCT/IB2022/059343	RK Pharma Inc/Apicore Pharma
Ferumoxytol	Improved process for the preparation of Ferumoxytol	India	IN 202223033400				10	6	2022	Complete	IN 202223033400	RK Pharma Inc/Apicore Pharma
Trabectedin	Storage-stable ready-to-use injectable formulations of Trabectedin	USA	US 20210361644				5	Aug	2021	Published	17394832	RK Pharma Inc
Ivacaftor	Improved process for the preparation of new polymorphs	India	IN 202241051153	7	9	2022				Complete	IN 202241051153	RK Pharma Inc
Ferumoxytol	Improved process for the preparation of Ferumoxytol	India	IN 202223058407							Complete	IN 202223058407	RK Pharma Inc/Apicore Pharma
Dolutegravir	Improved process for the preparation of Dolutegravir	India	IN 202241065264	15	11	2022	7	9	2022	Complete	IN 202241065264	RK Pharma Inc
Lumacaftor	New process for the prep of Lumacaftor intermediate	India	IN 202241058410	12	10	2022				Complete	IN 202241058410	RK Pharma Inc
Lurbinectedin	Lurbinectedin RTU formulations-	India	IN 202241071165	9	12	2022				Complete	IN 202241071165	RK Pharma Inc

PATENT

REEL: 067343 FRAME: 0101

Histirelin	Improved process for the Histirelin preparation	India	IN 202341015016	6	3	2023				Complete	IN 202341015016	RK Pharma Inc/Apicore Pharma
Odevexibat	Improved process for the Odevexibat	India	IN 202341015015	6	3	2023				Complete	IN 202341015015	RK Pharma Inc
Lurbinctedin	Improved process for the preparation of NI RK-2 Polymorph	India	IN 202343024250							Complete	IN 202343024250	RK Pharma Inc/Apicore Pharma
Lurbinctedin	Improved process for the preparation of NI RK-3 Polymorph	India	IN 202343025835				30	3	2023			
Odevexibat	Improved process for the Odevexibat Crystalline forms	India	IN 202341029309	22	4	2023	5	4	2023	Complete	IN 202343025835	RK Pharma Inc/Apicore Pharma
Pentosan	LM. Wt Pentosan Process	India	IN 202341029310	22	4	2023				Complete	IN 202341029309	RK Pharma Inc
Pentosan	LM. Wt Pentosan Compositions	India	IN 202341029311	22	4	2023				Provisional	IN 202341029310	RK Pharma Inc
Itraconazole	An efficient industrial process for the preparation of itraconazole intermediate.	India	IN 202141011373	17	3	2021				Provisional	IN 202141011373	Aktinos Pharma Pvt Ltd
Benzimidazole	Green process for the preparation of benzimidazole derivatives.	India	IN 201941030677	30	July	2019	23	July	2020	Published	IN 201941030677	Aktinos Pharma Pvt Ltd
Diketone	An improved process for the preparation of 4-Fluro- α -[2-Methyl-1-Oxopropyl]- γ -Oxo-N- β -N Diphenyl benzene butanamide.	India	IN 202141017375	14	4	2021	10	4	2022	Provisional	IN 202141017375	Aktinos Pharma Pvt Ltd
Itraconazole	A Novel process for the preparation of itraconazole and	India	IN 201841013556	4	9	2018	3	4	2019	Published	IN 201841013556	Aktinos Pharma Pvt Ltd

	intermediates of itraconazole.											
Pantaprazole	An improved process for preparing the 2-Chloromethyl- 3,4-Dimethoxy Pyridine hydrochloride.	India	IN 201841028783	31	7	2018	31	7	2019	Published	IN 201841028783	Aktinos Pharma Pvt Ltd
Brivaracetam	An improved process for the preparation of Brivaracetam Intermediate.	India	IN 202141047588	20	10	2021	10	10	2022	Published	IN 202141047588	Aktinos Pharma Pvt Ltd
Dolutegravir	An improved process for the preparation of Dolutegravir Intermediate.	India	IN 202141045410	6	10	2021	28	9	2022	Published	IN 202141045410	Aktinos Pharma Pvt Ltd
Itraconazole	An efficient industrial process for the preparation of itraconazole intermediate.	India	IN 202241021083	8	4	2022	1	4	2023	Complete	IN 202241021083	Aktinos Pharma Pvt Ltd
Diclofenac Sod	Aqueous injectable solution comprising diclofenac	USA	US 11,110,073				23	3	2018	Granted	15/933,937	RK Pharma Inc
Diclofenac Sod	Aqueous injectable solution comprising diclofenac	USA	US 11,850,224				18	8	2021	Granted	17/405,292	RK Pharma Inc
Diclofenac Sod	Aqueous injectable solution comprising diclofenac	USA	US 11,707,443				25	9	2020	Granted	17/032,395	RK Pharma Inc
Diclofenac Sod	Aqueous injectable solution comprising diclofenac	USA	US 20230301952				2	6	2023	Published	18/328,397	RK Pharma Inc
Lurbinectedin	Lurbinectedin RTU formulations-2 Bag	India	PCT/IN2023/051141	5	8	2023				PCT Application filed	IN 202341052714	RK Pharma Inc
2-bromo-4-	Process for the	India	IN 202341057265	24	8	2023				Provisional	IN 202341057265	RK Pharma Inc

PATENT

REEL: 067343 FRAME: 0103

nitroimidazole	preparation of 2-bromo-4-nitroimidazole																		
Tetrabenazine inter	New salt tetrabenazine Intermediate	India	IN 202341061463	13	9	2023													RK Pharma Inc
Indocynine Green	Indocyanine Green RTU	India	IN 202341065851	29	9	2023	29	8	2024	Provisional	IN 202341065851								RK Pharma Inc
Carbogetavir & rilpivirine	Sterile process for Carbogetagravir & Rilpivirine	India	IN 202441004238	21	1	2024				Provisional	IN 202441004238								RK Pharma Inc
Ecubectedin	Formulations of Ecubectedin	India	IN 202441009981	14	2	2024				Provisional	IN 202441009981								RK Pharma Inc
Ecubectedin	RTU formulations of Ecubectedin	India	IN 202441009980	14	2	2024				Provisional	IN 202441009980								RK Pharma Inc
Ecubectedin	Novel Process for Ecubectedin	India	IN 202441009974	14	2	2024				Provisional	IN 202441009974								RK Pharma Inc
Ecubectedin	New Polymorphs of Ecubectedin	India	IN 202441009972	14	2	2024				Provisional	IN 202441009972								RK Pharma Inc
Isavacoazonium sulphate	Improved process for Isacuvczonium sulphate	USA	US 20240010644A1				6	6	2023	Published	18/218, 610								RK Pharma Inc
Ivacator	Improved process for the preparation of new polymorphs	USA	18/462,619				7	9	2023	Complete Specs	18/462,619								RK Pharma Inc
Cetorelix	Cetorelix RTU Formulations	USA	US 18/682,785				9	2	2024	Complete Specs	US 18/682,785								RK Pharma Inc
Cetorelix	Cetorelix RTU Formulations	AUS	AU 2022325518				23	2	2024	Complete Specs	AU 2022325518								RK Pharma Inc
Cetorelix	Cetorelix RTU Formulations	NZ	NZ 808519				23	2		Complete Specs	NZ 808519								RK Pharma Inc
Ecubectedin	Formulations of Ecubectedin	India	IN 202441015858	6	3	2024				Provisional	IN 202441015858								RK Pharma Inc
Trimethyl sulfoxoniumbromide	Trimethyl sulfoxoniumbromide use in process prepn	India	IN 202441017240	11	3	2024				Provisional	IN 202441017240								RK Pharma Inc

PATENT